NASDAQ:RTRX - Retrophin Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $21.62 -0.58 (-2.61 %) (As of 01/22/2019 04:00 PM ET)Previous Close$22.20Today's Range$21.56 - $22.2452-Week Range$20.09 - $33.00Volume373,105 shsAverage Volume381,957 shsMarket Capitalization$891.78 millionP/E Ratio-14.41Dividend YieldN/ABeta1.21 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Retrophin, Inc., a biopharmaceutical company, focuses on the development, acquisition, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, and for adjunctive treatment of patients with peroxisomal disorders; and Thiola, a tiopronin tablet for the treatment of cystinuria. The company's product candidates consist of Fosmetpantotenate, a novel small molecule that is in Phase III clinical trial to treat pantothenate kinase-associated neurodegeneration; Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis; CNSA-001, an orally bioavailable proprietary form of sepiapterin that is in phase I clinical trial for the treatment of phenylketonuria; and Liquid Ursodeoxycholic Acid, a liquid formulation of ursodeoxycholic acid, which is in Phase III clinical trial for the treatment of primary biliary cholangitis. Retrophin, Inc. was founded in 2011 and is headquartered in San Diego, California. Receive RTRX News and Ratings via Email Sign-up to receive the latest news and ratings for RTRX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:RTRX Previous Symbol CUSIPN/A Webwww.retrophin.com Phone760-260-8600Debt Debt-to-Equity Ratio0.60 Current Ratio5.04 Quick Ratio4.99Price-To-Earnings Trailing P/E Ratio-14.41 Forward P/E Ratio-8.10 P/E GrowthN/A Sales & Book Value Annual Sales$154.94 million Price / Sales5.76 Cash FlowN/A Price / Cash FlowN/A Book Value$7.46 per share Price / Book2.90Profitability EPS (Most Recent Fiscal Year)($1.50) Net Income$-59,730,000.00 Net Margins-69.38% Return on Equity-35.43% Return on Assets-19.07%Miscellaneous Employees173 Outstanding Shares41,248,000Market Cap$891.78 million OptionableOptionable Retrophin (NASDAQ:RTRX) Frequently Asked Questions What is Retrophin's stock symbol? Retrophin trades on the NASDAQ under the ticker symbol "RTRX." How were Retrophin's earnings last quarter? Retrophin Inc (NASDAQ:RTRX) issued its quarterly earnings data on Thursday, November, 1st. The biopharmaceutical company reported ($0.92) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.53) by $0.39. The biopharmaceutical company earned $40.70 million during the quarter, compared to the consensus estimate of $44.36 million. Retrophin had a negative return on equity of 35.43% and a negative net margin of 69.38%. Retrophin's revenue for the quarter was up 1.0% on a year-over-year basis. During the same quarter last year, the company earned $0.15 EPS. View Retrophin's Earnings History. When is Retrophin's next earnings date? Retrophin is scheduled to release their next quarterly earnings announcement on Tuesday, February 26th 2019. View Earnings Estimates for Retrophin. What price target have analysts set for RTRX? 4 Wall Street analysts have issued 1-year target prices for Retrophin's shares. Their forecasts range from $43.00 to $57.00. On average, they expect Retrophin's stock price to reach $48.00 in the next twelve months. This suggests a possible upside of 122.0% from the stock's current price. View Analyst Price Targets for Retrophin. What is the consensus analysts' recommendation for Retrophin? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Retrophin in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Retrophin. Has Retrophin been receiving favorable news coverage? News articles about RTRX stock have been trending very positive on Tuesday, InfoTrie reports. InfoTrie identifies negative and positive media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Retrophin earned a news sentiment score of 3.2 on InfoTrie's scale. They also gave media headlines about the biopharmaceutical company a news buzz of 4.0 out of 10, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next several days. Who are some of Retrophin's key competitors? Some companies that are related to Retrophin include Horizon Pharma (HZNP), Intercept Pharmaceuticals (ICPT), Evotec (EVTCY), Agios Pharmaceuticals (AGIO), Emergent Biosolutions (EBS), Ascendis Pharma A/S (ASND), Blueprint Medicines (BPMC), HUTCHISON CHINA/S (HCM), Ultragenyx Pharmaceutical (RARE), Akcea Therapeutics (AKCA), ACADIA Pharmaceuticals (ACAD), Global Blood Therapeutics (GBT), Ligand Pharmaceuticals (LGND), Amicus Therapeutics (FOLD) and Reata Pharmaceuticals (RETA). Who are Retrophin's key executives? Retrophin's management team includes the folowing people: Mr. Stephen J. Aselage, CEO, Pres & Director (Age 67)Ms. Laura M. Clague CPA, CFO & Sr. VP (Age 59)Mr. Neil F. McFarlane, Chief Operating Officer (Age 45)Ms. Elizabeth E. Reed, Sr. VP, Gen. Counsel & Corp. Sec. (Age 47)Dr. William E. Rote, Sr. VP of R&D (Age 55) Who are Retrophin's major shareholders? Retrophin's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Bank of Montreal Can (0.43%) and Handelsinvest Investeringsforvaltning (0.16%). Company insiders that own Retrophin stock include Elizabeth E Reed, Laura Clague, Neil F Mcfarlane, Steve Aselage and William E Rote. View Institutional Ownership Trends for Retrophin. Which major investors are selling Retrophin stock? RTRX stock was sold by a variety of institutional investors in the last quarter, including Bank of Montreal Can. Company insiders that have sold Retrophin company stock in the last year include Elizabeth E Reed, Laura Clague, Neil F Mcfarlane, Steve Aselage and William E Rote. View Insider Buying and Selling for Retrophin. Which major investors are buying Retrophin stock? RTRX stock was purchased by a variety of institutional investors in the last quarter, including Handelsinvest Investeringsforvaltning. View Insider Buying and Selling for Retrophin. How do I buy shares of Retrophin? Shares of RTRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Retrophin's stock price today? One share of RTRX stock can currently be purchased for approximately $21.62. How big of a company is Retrophin? Retrophin has a market capitalization of $891.78 million and generates $154.94 million in revenue each year. The biopharmaceutical company earns $-59,730,000.00 in net income (profit) each year or ($1.50) on an earnings per share basis. Retrophin employs 173 workers across the globe. What is Retrophin's official website? The official website for Retrophin is http://www.retrophin.com. How can I contact Retrophin? Retrophin's mailing address is 3721 VALLEY CENTRE DR. SUITE 200, SAN DIEGO CA, 92130. The biopharmaceutical company can be reached via phone at 760-260-8600 or via email at [email protected] MarketBeat Community Rating for Retrophin (NASDAQ RTRX)Community Ranking: 3.0 out of 5 ( )Outperform Votes: 307 (Vote Outperform)Underperform Votes: 205 (Vote Underperform)Total Votes: 512MarketBeat's community ratings are surveys of what our community members think about Retrophin and other stocks. Vote "Outperform" if you believe RTRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RTRX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/22/2019 by MarketBeat.com StaffFeatured Article: Can individual investors take part in an IPO?